Outbreaks of Zika virus have been reported in several areas including tropical Africa, Southeast Asia and the Pacific Islands. This infectious disease can lead to microcephaly and other severe fetal brain defects, which presents a significant public health challenge. Because of this, an effective Zika vaccine is urgently needed, but there are delays in development due to a number of complexities.

Discover the role of a clinical trial vaccine lab in Zika vaccine development and how you can proactively avoid challenges along the development continuum.

Authors:
Wayne Hogrefe, Ph.D., D (ABMLI), Vice President, Vaccine unit
Paul Rhyne, Ph.D.

Complete the form below to access this insight brief